Valion Bio, Inc. (VBIO) Diversifiers

Equity · Currency in USD · Last updated Jun 4, 2026

Valion Bio, Inc. (formerly Tivic Health Systems) is a late-stage biopharmaceutical company developing Entolimod, a TLR5 agonist with FDA Fast Track and Orphan Drug designations for Acute Radiation Syndrome under the FDA's Animal Rule pathway, with related programs for neutropenia, lymphocyte exhaustion, and the chronic-use variant Entolasta.

Looking to balance out your exposure to VBIO? The ETFs below have the lowest correlation with VBIO — they tend to move on their own, which can help reduce risk when VBIO drops. The stock ideas table highlights individual companies that behave independently from VBIO.

No Diversifiers Found for VBIO

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements VBIO

Add VBIO to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with VBIO